Publication | Closed Access

Bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as the second-line therapy for patients with metastatic colorectal cancer, a multicenter study

MedicinePharmacologyColorectal CancerMetastatic Colorectal CancerPharmacotherapyAnti-cancer AgentCancer TreatmentMulticenter StudySecond-line TherapyOncologyRadiation Oncology